Armata Pharmaceuticals, Inc. (ARMP)

NYSEAMERICAN: ARMP · IEX Real-Time Price · USD
3.000
+0.100 (3.45%)
Feb 23, 2024, 4:00 PM EST - Market closed
3.45%
Market Cap 108.44M
Revenue (ttm) 4.05M
Net Income (ttm) -59.51M
Shares Out 36.15M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,998
Open 2.900
Previous Close 2.900
Day's Range 2.900 - 3.000
52-Week Range 1.070 - 5.260
Beta 0.71
Analysts Strong Buy
Price Target 7.00 (+133.33%)
Earnings Date Mar 14, 2024

About ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacterio... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Deborah L. Birx M.D.
Employees 72
Stock Exchange NYSEAMERICAN
Ticker Symbol ARMP
Full Company Profile

Financial Performance

In 2022, ARMP's revenue was $5.51 million, an increase of 23.11% compared to the previous year's $4.47 million. Losses were -$36.92 million, 59.4% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ARMP stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(133.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...

4 days ago - PRNewsWire

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

LOS ANGELES , Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...

3 months ago - PRNewsWire

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

LOS ANGELES , Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...

4 months ago - PRNewsWire

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutic...

4 months ago - PRNewsWire

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of...

5 months ago - PRNewsWire

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

MARINA DEL REY, Calif., Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics fo...

5 months ago - PRNewsWire

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

LOS ANGELES , Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut...

6 months ago - PRNewsWire

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

MARINA DEL REY, Calif. , May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...

9 months ago - PRNewsWire

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

MARINA DEL REY, Calif. , May 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...

10 months ago - PRNewsWire

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

MARINA DEL REY, Calif., March 16, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

AP-PA02 is well-tolerated and data supports progression to Phase 2b Also announces first subject dosed in Phase 2 'Tailwind' clinical trial of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bron...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

Other symbols: INVA
1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

MARINA DEL REY, Calif. , Dec. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

1 year ago - PRNewsWire

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

MARINA DEL REY, Calif. , Nov. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

MARINA DEL REY, Calif. , Aug. 11, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for dif...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

Study conducted in partnership with the US Department of Defense MARINA DEL REY, Calif. , May 23, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

MARINA DEL REY, Calif , May 12, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

MARINA DEL REY, Calif. , March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriopha...

Other symbols: INVA
2 years ago - PRNewsWire

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

MARINA DEL REY, Calif., March 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag...

2 years ago - PRNewsWire

HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in West Los Angeles

LOS ANGELES & DENVER--(BUSINESS WIRE)-- #Bioscience--HATCHspaces®, NexCore Group, and Nuveen Real Estate have acquired a 56,300 SF Industrial Building to convert to Biomanufacturing in West Los Angele...

2 years ago - Business Wire

Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

MARINA DEL REY, Calif., Feb. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...

2 years ago - PRNewsWire

Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences

MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...

2 years ago - PRNewsWire

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

MARINA DEL REY, Calif., Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

Other symbols: INVA
2 years ago - PRNewsWire